Crowley Elizabeth
Known title: Sr. VP &CPDOCIK: 0001681854
Associated companies
Transaction History
| CLDX | ▲ Buy | Option Exercise | 30,000 | $311K | 6/14/2024 | View on chart |
| CLDX | ▼ Sell | Open Market | 30,000 | $1.0M | 6/14/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 7,500 | $78K | 6/7/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 7,500 | $68K | 6/7/2024 | View on chart |
| CLDX | ▼ Sell | Open Market | 15,000 | $526K | 6/7/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 34,445 | $96K | 5/30/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 8,500 | $77K | 5/30/2024 | View on chart |
| CLDX | ▼ Sell | Open Market | 38,597 | $1.3M | 5/30/2024 | View on chart |
| CLDX | ▼ Sell | Open Market | 4,000 | $160K | 12/8/2021 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 4,000 | $36K | 12/8/2021 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 8,555 | $24K | 11/1/2021 | View on chart |
| CLDX | ▼ Sell | Open Market | 2,528 | $112K | 11/1/2021 | View on chart |
| CLDX | ▼ Sell | Open Market | 600 | $26K | 11/1/2021 | View on chart |
| CLDX | ▼ Sell | Open Market | 1,189 | $49K | 11/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Celldex shares dip after positive Phase 3 barzolvolimab results
Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.
Celldex shares dip after positive Phase 3 barzolvolimab results. Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.